We are a Germany-based biotechnology company, located in Hamburg, with a keen focus on the provision of top quality tests for tropical and emerging infectious diseases.
Leveraging our patented technology platform, our immunoassay tests have superior specificity and sensitivity, especially targeting the priority diseases in the WHO blueprint list. The outstanding performance characteristics of our tests have proven that we are providing the best tools for scientists, researchers and health authorities for their tasks of outbreak monitoring, infection surveillance, and seroprevalence studies.
A long-term, impactful partnership is central to achieving our shared vision.
Bernhard Nocht Institute for Tropical Medicine (BNITM) is one of the most reputed institutes in their field and is dedicated to research, teaching, training and further education as well as counselling and care in the fields of tropical diseases and emerging infectious diseases.
Panadea and BNITM have established a long-term partnership for innovations and technical solutions for people and society.
The scientific advisory board offers advice on Panadea´s scientific direction and evaluates Panadea´s scientific quality. The board is comprised of internationally renowned experts in the field of tropical and emerging infectious diseases.
